2021 DORIS definition of remission in SLE: final recommendations from an international task force

van Vollenhoven R. F., Bertsias G., Doria A., Isenberg D., Morand E., Petri M. A., ...Daha Fazla

LUPUS SCIENCE & MEDICINE, cilt.8, sa.1, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 8 Sayı: 1
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1136/lupus-2021-000538
  • Dergi Adı: LUPUS SCIENCE & MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals
  • Anahtar Kelimeler: lupus erythematosus, systemic, outcome assessment, healthcare, therapeutics, DISEASE-ACTIVITY STATE, PROLONGED REMISSION, COHORT, LDAS
  • İstanbul Üniversitesi Adresli: Evet

Özet

Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. Methods Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. Results Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator's Global Assessment <0.5 (0-3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. Conclusion The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.